|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.365 SEK | +3.05% |
|
-4.64% | -8.33% |
| Jun. 28 | Biovica to Provide Biomarker Testing for US Biopharmaceutical Company | MT |
| Jun. 28 | Biovica International Signs New Agreement Supporting Pharma Development | CI |
Biovica International AB (publ) reported earnings results for the full year ended April 30, 2024. For the full year, the company reported sales was SEK 7.29 million compared to SEK 4.96 million a year ago. Revenue was SEK 8.3 million compared to SEK 5.7 million a year ago.
Net loss was SEK 124.82 million compared to SEK 110.49 million a year ago. Basic loss per share from continuing operations was SEK 2.14. Diluted loss per share from continuing operations was SEK 2.14.
| 1st Jan change | Capi. | |
|---|---|---|
| -8.33% | 18.88M | |
| -37.33% | 8.55B | |
| +14.86% | 3.8B | |
| +7.38% | 2.44B | |
| -25.96% | 1.87B | |
| -17.30% | 1.74B | |
| +36.49% | 1.19B | |
| +32.58% | 830M | |
| -7.64% | 711M | |
| -18.37% | 589M |
BIOVICA INTERNATIONAL AB 
